GET DAILY SIGNALSargenx SE (ARGX) Delivers Solid Q3 2026 Results Amid VYVGART Growth
Key Takeaways
- argenx SE (ARGX) reported total third quarter 2026 revenue of $1.75 billion, up from $1.15 billion in the same period a year earlier, driven by continued VYVGART momentum.
- Product net sales reached $1.7 billion, reflecting growth of 54% year over year and 13% quarter over quarter.
- Diluted earnings per share (EPS) came in at $7.80, just below the analyst consensus estimate of $7.90, while revenue topped the roughly $1.65 billion consensus figure.
- Net income rose to $506 million from $344 million a year ago, and operating profit increased to $486 million.
- The company raised its full-year 2026 expense outlook to approximately $4 billion for combined research and development (R&D) and selling, general and administrative (SG&A) costs, partly reflecting the Forte Biosciences acquisition.
Why These Results Stand Out
argenx's third quarter results matter because they show whether its flagship therapy, VYVGART (efgartigimod), can keep converting clinical success into commercial growth across multiple indications. The company has rapidly scaled from a research-stage biotech into a profitable, global immunology player, making each quarterly update a key signal on patient adoption, pricing trends, and operating leverage. This particular report also carried added weight because it was the first full quarter following the acquisition of Forte Biosciences, which reshaped the expense base and pipeline. Investors were watching closely to see whether accelerating revenue growth could offset a meaningful step-up in spending while the company pursues its broader "Vision 2030" expansion strategy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
argenx reported total third quarter 2026 revenue of $1.75 billion, an increase from $1.15 billion in the prior-year period. Product net sales were $1.7 billion, up 54% year over year and 13% quarter over quarter, led by VYVGART across its approved uses. On a geographic basis, U.S. product net sales were approximately $1.5 billion, followed by $81 million in Japan and $158 million across the rest of the world, with a further $11 million from product supply to Zai Lab in China.
Net income rose to $506 million from $344 million a year earlier. Basic EPS was $8.07 compared with $5.61 in the prior-year quarter, while diluted EPS was $7.80 versus $5.18. Operating profit was $486 million, representing an operating margin of 28%, or about 37% when excluding roughly $150 million of transaction-related costs tied to the Forte acquisition. Relative to expectations, revenue of approximately $1.72 billion exceeded the consensus estimate near $1.65 billion, while diluted EPS of $7.80 landed just below the $7.90 analyst consensus. The company ended the quarter with $3.7 billion in cash, cash equivalents, and current financial assets after paying a net $2.1 billion for Forte. From what I see, the underlying commercial momentum here looks durable.
Market Reaction and Sentiment
The initial market response to argenx's third quarter report was mixed but leaned positive. Shares closed 2.34% higher at $890.05 on the Nasdaq following the release, though the stock traded lower in overnight activity. The modestly negative EPS surprise was largely offset by a revenue beat and a strong underlying growth narrative around VYVGART, suggesting investors were more focused on commercial momentum and the franchise's trajectory than on a single quarter's per-share figure. The Forte-related expense step-up appeared to be well understood, with the market weighing the near-term cost against the company's expanding pipeline and long-term growth objectives.
Looking Ahead at Key Catalysts
argenx now expects combined R&D and SG&A expenses of approximately $4 billion for full-year 2026, an increase that includes Forte transaction-related costs, investment in FB-102, ongoing pipeline advancement, and commercial infrastructure buildout following positive clinical data. Management framed the higher spending as deliberate reinvestment from a position of financial strength, with the company supporting 10 clinical-stage assets.
Investors should watch several catalysts in the coming quarters. The seronegative label expansion in generalized myasthenia gravis (gMG) remains an important growth driver, and management highlighted supplemental regulatory filings for ocular and pediatric indications, with a pediatric PDUFA (Prescription Drug User Fee Act) date set for February 2027. Continued patient additions in CIDP (chronic inflammatory demyelinating polyneuropathy), adoption of the prefilled syringe, and progress in autoimmune myositis will all influence the commercial runway.
On the cost side, the key question is whether revenue growth continues to outpace expense growth, preserving the operating leverage the company demonstrated this quarter once transaction-related items are excluded. Balance-sheet flexibility remains a focus after the Forte deal, and investors will be tracking pipeline readouts and any updates to Vision 2030 goals as the company balances growth investment against profitability. I’m watching this closely as the next few quarters should clarify the pace of that leverage.
Refining Analysis with Tickeron Tools
In pulling together my review of argenx SE (ARGX), I turned to Tickeron’s AI Screener to quickly surface comparable names in the biotech space and test how the company’s growth metrics stack up against peers. The tool’s ability to combine technical patterns with fundamental filters helped me cross-check revenue trends and margin expansion without spending hours on manual screens. It’s become a regular part of my process when evaluating names like this one, especially after major acquisitions or label updates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARGX's RSI Oscillator climbs out of oversold territory
The RSI Indicator for ARGX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 16 of the 20 cases the stock moved higher. This puts the odds of a move higher at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 55 cases where ARGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for ARGX just turned positive on October 21, 2026. Looking at past instances where ARGX's MACD turned positive, the stock continued to rise in 37 of 49 cases over the following month. The odds of a continued upward trend are 76%.
Following a +7.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 217 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ARGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
ARGX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARGX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Aroon Indicator for ARGX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.615) is normal, around the industry mean (2.988). P/E Ratio (32.074) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (438.009).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of antibody-based medicines
Industry Biotechnology
Advertisement